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Abstract. 
Background and Aims: Radiofrequency ablation (RFA) can play an important role in the 
treatment of primary or metastatic liver tumors. Currently, percutaneous RFA is generally re-
garded as a safe, effective, and minimally invasive procedure. This study aimed to evaluate 
the presence and course of pleural effusion after monopolar RFA. 
Methods: From October 2008 to July 2013, a total of 54 patients (28 male and 26 female, 
mean age 65.2) treated with monopolar RFA were included in our study. 47 patients were di-
agnosed with hepatocellular carcinoma, 4 patients with hepatic metastasis, and 3 patients had 
other diagnoses. There were a total of 115 sessions of treatment and 199 liver tumors to be 
treated (1.73 ± 1.02 tumors treated per session). The tumor size ranged from 0.8 cm to 5.0 cm 
(mean 2.31 cm, standard deviation 1.04 cm). Thereafter, a follow-up ultrasound was per-
formed within 24 hours subsequent to ablation to evaluate the presence of pleural effusion. 
The degree of pleural effusion was assessed by chest X-ray. 
Results: Fifteen (13.0%) treatment sessions in 14 patients showed right-sided pleural effusion 
after ablations. One patient had a large amount of effusion, while other patients manifested a 
minimal to small amount of effusion. There were 5 patients that experienced delayed resolu-
tion of pleural effusion; one patient (0.87%) had a minimal amount of pleural effusion even 
after one month. Overall, there was no pneumothorax, or periprocedural morality. Age, gender, 
tumor numbers, tumor sizes, and complete ablation of target tumors were similar among 
groups presenting with or without pleural effusion. Tumor locations associated with S78 seg-
ments abutting the diaphragm or right lobe of the liver were not associated with development 
of pleural effusion. Only the duration of ablation time had a marginal trend toward signifi-
cance (p = 0.051). 
Conclusions: The transient appearance of right-sided pleural effusion after percutaneous RFA 
for hepatic malignancies was not infrequent. However, refractory pleural effusion was rare. 
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方法：本研究共收入 54 位(28 位男性與 26 位女性，平均年齡 65.2 歲)接受單極經皮射頻
消融術患者。其中 47 位的診斷為肝細胞癌、4 位為肝轉移癌、3 位為其他肝臟惡性腫瘤。
本研究收入總共 115 次的射頻消融術治療 199 顆肝腫瘤(每次治療平均消融 1.73 ± 1.02 顆
腫瘤)。腫瘤大小為 0.8 到 5.0 公分(平均 2.31 公分，標準差 1.04 公分)。在射頻消融術後
24 小時內，患者接受超音波追蹤評估是否有肋膜積液，存在肋膜積液的患者以胸部 X 光
評估肋膜積液量。 














Liver cancer has been one of the leading causes of 
cancer-related morality worldwide [1]. Within the 
liver cancer category, hepatocellular carcinoma (HCC) 
was the most commonly diagnosed primary liver can-
cer. Local ablation therapies were considered to be 
effective treatments for early stage HCC [2,3]. Ra-
diofrequency ablation (RFA) was deemed more effec-
tive than other local ablation modalities in HCC 
treatment for its high rate of technique effectiveness, 
low local recurrence rate, and good prognosis [4]. Re-
cently, RFA was reported to be an effective treatment 
for small and medium-sized HCCs using the multiple 
electrode switching system [5]. Secondary liver tu-
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mors are malignant tumors that metastasize into the 
liver from other sites of the body. Percutaneous RFA 
was reported to achieve local control of secondary 
liver tumors such as colorectal and breast metastases 
[6,7]. The mid-term and long-term survival rates of 
patients with treated hepatic metastases were compa-
rable to those survival rates of patients with resected 
hepatic metastases [6,8,9]. 
Percutaneous RFA had been regarded as a safe and 
minimally invasive procedure. The reported complica-
tions associated with RFA include ascites, hemorrhage, 
pleural effusion, abscess formation, biloma, subcap-
sular hematoma, and liver failure [10]. The reported 
major complication rate ranged from 3.54 to 4.4% 
[10,11], and thoracic-related major complications in-
cluding hemohydrothorax, hepatohydrothorax, or 
pneumothorax were rare. Most notably, the mortality 
rate related to RFA was reported as less than 0.5% 
[10,11]. 
The presence of pleural effusion was rarely dis-
cussed in the list of complications related to percuta-
neous RFA for hepatic malignancies. The course and 
nature of pleural effusion or subsequent pleural effu-
sion has not yet to be addressed as a stand-alone topic. 
This study aimed to evaluate the presence and course 
of pleural effusion after RFA for hepatic malignan-
cies. 
 
MATERIALS AND METHODS 
 
Patients 
This study retrospectively evaluated and included 
patients who underwent RFA procedures for hepatic 
malignancies from October 2008 to July 2013. The 
following inclusion criteria were used: (1) primary or 
secondary malignancies were diagnosed by patholog-
ical studies except HCC, which can be diagnosed ac-
cording to the criteria from the guidelines of the 
American Association for the Study of Liver Diseases 
published in 2010 (typical enhancing patterns in 
computed tomography or magnetic resonance imaging 
studies) [3], (2) diameter of the largest tumor was less 
than 5 cm regardless of tumor numbers. A patient was 
excluded from this study if there were pre-existing 
pleural effusion, or iatrogenic injection of pleural ef-
fusion or ascites during ablation procedure. 
 
Radiofrequency Ablations (RFA) 
The internally cooled 17-gauge monopolar radiof-
requency electrode (ValleyLab) with an electrically 
active tip was placed under real time sonographic 
monitoring with a 1-5 MHz convex probe (C5-1, 
Philip) on an iU22 ultrasound system (Philips), by 
way of a percutaneous puncture through the inter-
costal space or upper abdomen to the liver by a single 
experienced operator. The radiofrequency energy was 
generated with a 480-kHz power generator (Series 
CC-1, ValleyLab) with a maximum power of 200 
watts and delivered to each electrode. The delivery of 
energy was regulated with a feedback algorithm ac-
cording to tissue impedance. For larger tumors in this 
study, two or three electrodes were inserted and an 
additional switcher shifted the ablation energy be-
tween the electrodes. Regardless of the number of 
electrodes, RF energy was delivered only via one 
electrode once at same time for 30 seconds unless the 
tissue impedance had an abrupt rise when the energy 
output was switched to the next electrode. A pump 
(model PEPM, ValleyLab) maintained continuous 
circulation of chilled distilled water through the elec-
trodes to keep the electrode tip temperature within 0 to 
10°C. During the process of electrode removal, tract 
ablation was performed. A single operator performed 
all the RFA procedures in this study. For conscious 
sedation, the patients received either meperidine in 
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addition to midazolam, or intravenous general anes-
thesia without endotracheal intubation or mechanical 
ventilation. We monitored patient vital signs, electro-
cardiogram, and oxygen saturation during RFA. 
 
Follow-up 
A follow-up ultrasound was performed within 24 
hours after the procedure to evaluate the complica-
tions and the presence of pleural effusion. Upright 
chest X-ray was performed if the presence of pleural 
effusion was detected by ultrasound, and thereafter 
evaluated by an experienced pneumologist to assess 
the degree of pleural effusion. The amount of pleural 
effusion was estimated based on the patient’s chest 
X-ray. A minimal amount of pleural effusion was de-
fined as the posterior costophrenic sulcus being ob-
scured. Small amount was defined as obliteration of 
the lateral costophrenic sulcus. Moderate amount was 
defined as haziness of the diaphragmatic contour. The 
effusion above the level of the 4th anterior rib in up-
right chest X ray was defined as large amount [12]. 
One month after the procedure, a contrast-enhanced 
CT or MR imaging was performed to assess the RFA 
effectiveness. Multi-phase imaging studies including 
unenhanced, arterial, portal, and venous phases were 
applied if the malignancy being treated was HCC. 
Complete ablation was defined as the target lesions 
being surrounded by non-enhanced areas on contrast- 
enhanced CT or MR. Delayed resolution of pleural 
effusion was defined as the presence of pleural effu-
sion after one week but not at the one-month imaging 
follow-up. Refractory pleural effusion was defined as 
the presence of pleural effusion at the one-month im-
aging follow-up. The patients were then regularly fol-
lowed every 3 months with either ultrasound or con-
trast-enhanced CT or MR imaging. 
 
Statistical Analysis 
 We compared age, numbers and sizes of tumors, 
and RF ablation time between the treatment sessions 
with and without occurrence of pleural effusion after 
RFA using the Wilcoxon rank sum test. Fisher’s exact 
test was applied to the categories of gender and the 
occurrence of pleural effusion. The described statisti-
cal analyses were performed using the IBM SPSS Sta-
tistics for Windows, Version 20.0. A two-tailed prob-




Table 1. Patient characteristics at the baseline of radio frequency ablation 
 Patients (n=54) 
Age (year) 65.2 ± 11.2 (39.6-84.9) 
Gender  
 Male 28 (51.9%) 
 Female 26 (48.1%) 
Etiology of liver cancer  
 Hepatocellular carcinoma 47 (87.0%) 
 Hepatic metastasis 4 (7.4%) 
 Cholangiocarcinoma 1 (1.9%) 
 Others 2 (3.7%) 
Size of largest tumor (cm) 2.31 ± 1.04 (0.8-5.0) 
Follow-up (months) 27.2 ± 16.9 (2-64) 
Note. Data presented with plus–minus values are means ± SD 
 
 




This study included a total of 54 patients (28 male 
and 26 female). Patient age at baseline of treatment 
ranged from 39.6 to 84.9 (mean 65.2) years old. There 
were 47 patients that had hepatocellular carcinoma, 4 
patients had hepatic metastasis, 1 patient had cholan-
giocarcinoma, 1 patient had neuroendocrine tumor, 
and 1 patient had malignant angiomyolipoma. A total 
of 115 sessions of treatment were included in this 
study. A total of 199 liver tumors were treated (1.73 ± 
1.02 tumors treated per session) with tumor sizes 
ranging from 0.8 cm to 5.0 cm (mean 2.31 cm, stand-
ard deviation 1.04 cm). Table 1 provides a summary 
of the patient characteristics. 
 
Pleural Effusion 
Pleural effusion was noted after ablation proce-
dures in 15 treatment sessions from 14 patients. All of 
these pleural effusions presented on the right side. 
Seven patients had a minimal amount of pleural effu-
sion, and six patients had a small amount. Only 1 pa-
tient had a large amount of effusion. Delayed resolu-
tion of pleural effusion 1 week after treatment was 
noted in 5 patients, but the pleural effusion was com-
pletely resolved on the imaging studies 1 month after 
RFA. Only 1 female patient had minimal amount of 
pleural effusion one month after RFA. She received 2 
consecutive RFA sessions and had a moderate amount 
of pleural effusion after RFA. There was no pneumo-
thorax or periprocedural morality that occurred in this 
study. None of the patients in this study had evidence 
of pleural seeding of HCC in their clinical course fol-
lowing RFA. 
Age and gender were not statistically related to the 
presence of pleural effusion. The numbers and sizes of 
tumors to be treated were also not related to the pres-
ence of pleural effusion. Tumor locations regarding 
S78 segments abutting the diaphragm or right lobe of 
liver were not associated with development of pleural 
effusion. Only the total ablation time defined by the 
duration of ablation time had a marginal trend toward 
significance (p = 0.051). The presence of pleural effu-
sion did not have impacts on the technique effective-
ness assessed at 1 month after RFA. 
 
DISCUSSION 
RFA was regarded as a safe, effective, but less in-
vasive procedure for treating hepatic malignancies. 
The published literatures for complications of RFA 
were limited. In a previous multicenter study includ-
ing 2320 patients in Italy, the mortality rate and over-
all complication rate of percutaneous RFA in treating 
malignant liver tumors were 0.3% and 7.1% respec-
tively [13]. In a recent Japanese multicenter study in-
cluding 16,346 treated nodules reported that the mor-
tality rate was 0.038% and the overall complication 
rate was 3.54% in percutaneous RFA of hepatocellular 
carcinoma. The reported complications included 276 
hepatic injuries (1.69%), 113 extrahepatic organ inju-
ries, 78 hemorrhages (0.477%), and 27 tumor progres-
sions (0.17%). Among the extrahepatic organ injuries, 
there were a total of 43 cases of refractory pleural ef-
fusion (0.263%) reported. However, this study did not 
mention the prevalence, nature, and course of post- 
Table 2. Characteristics of pleural effusion 
Variables No. of patient 
Amount of effusion (minimal/small/moderate/large) 7/6/0/1 
Location of pleural effusion (right/left) 14/0 
Delayed resolution of effusion 5 (35.7%) 
Refractory pleural effusion 1 (7.1%) 
 
 
26 W. C. Chao et al./JCRP 2(2015) 22-30
RFA pleural effusions [11]. 
In our study, the transient appearance of pleural 
effusion in patients receiving percutaneous RFA for 
hepatic malignancies was quite frequent. Most of the 
pleural effusion was right-sided and the amount of 
fluid was limited. None of these patients with transient 
and minimal amount of pleural effusion required 
therapeutic thoracentesis. We did not observe major 
mortality contributed to pleural effusion in this study 
or periprocedure mortality related to RFA in this study. 
A longer duration of ablation time might have a mar-
ginal trend toward formation of pleural effusion after 
RFA. 
The pleural liquid was normally originated from 
circulation of the pleural membranes. The fluid was 
finally reabsorbed by the lymphatics in the parietal 
pleura. The formation and reabsorption of pleural ef-
fusion was general in equilibrium. Breaking the equi-
librium toward either increasing formation or de-
creasing reabsorption of fluid may cause accumulation 
of pleural effusion in the pleural space. However, the 
pleural effusion was commonly a result of combina-
tion of troubles in both formation and reabsorption. 
Increased permeability of pleural membrane, in-
creased vascular pressure of pleural microcirculation, 
decreased osmotic pressure of the third space, or de-
creased pressure in the pleural cavity can lead to in-
creased formation of pleural fluid [14]. 
The lymphatic function was pivotal in reabsorp-
tion of pleural effusion [15]. Multiple factors were 
reported to interfere lymphatic function. These factors 
can be divided into intrinsic and extrinsic categories. 
The intrinsic ones were usually related to lymphatic 
functions. The common factors in this category were 
reported as inflammation or injuries of lymphatic duct, 
endocrine disorders, or cancer invasion of lymphatic 
duct. The extrinsic factors including diaphragm paral-
ysis, pneumothorax, pleural fibrosis, or increases in 
venous pressure hindered the lymphatic drainage 
without direct involvement of the lymphatic structures. 
Mostly, the development of pleural effusion originated 
from multiple factors comprising both intrinsic and 
extrinsic ones. 
One of the possible mechanisms for pleural effu-
sion after RFA was caused by transient pleurisy relat-
ed to thermal effects. The direct thermal damage of 
pleural membranes might cause increased pleural ca-
pillary filtration and interferes with parietal pleural 
Table 3. Characteristics of RFA procedures in patients with and without pleural effusion 
 Presence of pleural effusion after RFA (no. of treatment session) 
 Yes (n=15) No (n=100) P-value 
Age at treatment (year) 63.8 ± 8.0 66.7 ± 10.8 0.229 
Gender (M/F) 6/9 52/48 0.420 
Number of tumors to treat 1.93 ± 1.22 1.70 ± 0.99 0.490 
Size of tumors to treat (cm) 2.57 ± 1.39 2.27 ± 0.98 0.714 
Tumor pathology (HCC / others) 13/2 86/14 1.000 
Tumor location    
    Right liver (yes/no)* 13/2 74/26 0.354 
    S7/8 (yes/no)* 9/6 42/58 0.266 
Ablation time (minutes) 32.6 ± 18.76 23.38 ± 13.65 0.051 
Effectiveness at 1 month (yes/no) 13/2 89/7 0.606 
* At least one ablated tumor in the treatment session was located in the designated location 
RFA, radiofrequency ablation 
 
 































Figure 1. Periprocedural chest X-rays. (A) absence of pleural effusion before RFA (B) large 
amount of pleural effusion, 2 days after RFA (C) partial regression of right pleural 
effusion, 9 days after RFA (D) complete resolution of right-sided pleural effusion 
one month after RFA without thoracentesis 
 
 
lymphatic fluid removal. That explanation was sup-
ported by the findings in this study that RFA proce-
dures with the presence of pleural effusion after 
treatment had longer duration of ablation time than 
those without pleural effusion. Some maneuvers were 
reported to reduce damages to the diaphragm. First, 
increasing visibility of hepatic tumors near the hepatic 
dome could decrease the probabilities of unintentional 
direct damages caused by improper positioning of 
electrodes. The visibility of hepatic tumors in the he-
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patic dome treated by percutaneous RFA could be 
enhanced through creating artificial ascites or pleural 
effusion [16,17]. Second, separating the diaphragm 
and the liver by fluid could decrease the collateral 
thermal injuries. In vivo porcine studies showed that 
the injection of artificial ascites decreased thermal 
damage caused by RFA near the diaphragm [18]. A 
recent study showed that artificial ascites significantly 
reduced thermal damage to the diaphragm caused by 
RFA for HCC in the hepatic dome without compro-
mising technique effectiveness [19]. 
Additionally, liquid can move across the dia-
phragm. Peritoneal liquid can reach the pleural space 
by diffusing across the mesothelial layers. Defects in 
the diaphragm may lead to rapid movement of liquid 
across the diaphragm [20]. The patient who developed 
a large amount pleural effusion after RFA had liver 
cirrhosis with massive, refractory ascites prior to the 
RFA treatment. The rapid movement of fluid into the 
pleural cavity might be related to damage of the dia-
phragm. Although the patient had mild respiratory 
distress on exertion in the first week after RFA, the 
symptoms were not severe enough to require a thera-
peutic thoracentesis. The patient refused diagnostic 
thoracentesis due to underlying thrombocytopenia. 
The pleural effusion was resolved completely and 
spontaneously in the CT imaging one month after 
RFA. Thus, the damage to the diaphragm was likely to 
be healed completely. 
In the present study, the majority of the pleural 
effusion developed after RFA, was right-sided and 
minimal to small amount. Thereafter, the effusion re-
absorbed spontaneously within 3 to 7 days. The only 
case with refractory pleural effusion after RFA had a 
moderate to massive amount of pleural effusion with 
delay resolution. The patient underwent a thoracen-
tesis 2 weeks later after the first session of RFA 
treatment. The effusion was exudative with high pro-
tein ratio based on Light’s criteria. The microbiology 
and cytology studies were unremarkable. However, 
the patient had tumor invasion of major vessels and 
multiple distant metastases found within 1 month after 
RFA. The invasion of major vessels may imply in-
volvement of the lymphatic system adjacent to the 
liver, which could hamper the lymphatic function and 
contribute to the poor resolution of pleural effusion. 
 This study had some limitations. The character-
istics of the pleural effusion were not evaluated in 
every case due to technically difficulties and potential 
complications in aspirating a minimal amount of effu-
sion. Also, this study might not detect the presence of 
pleural effusion if the fluid was below the detectable 
limit of a chest X-ray. The study was retrospective in 
design. Thus, we cannot confirm all the pleural effu-
sion was exudative or transudative, and we cannot 
completely rule out complications such as hemothorax, 
chylothorax, or bile duct fistula formation. However, 
chylothorax or bile duct fistula usually had a more 
complicated course and the pleural fluid in those situ-
ations was usually refractory. The only patient with 
refractory pleural effusion received thoracentesis to 
confirm the nature of pleural effusion. Moreover, after 
pleural effusion was first recognized, the follow-up 
chest X-ray film was based on decisions of the prima-
ry care physician according to the patient’s symptoms. 
In summary, the development of pleural effusion 
after RFA was not uncommon. The pleural effusion 
was predominantly right-sided. Most pleural effusion 
occurred after RFA was well tolerated and was re-
solved spontaneously without requirement of thora-
centesis. Refractory pleural effusion was rare. Ther-
mal injuries related to pleurisy and injuries to the dia-
phragm were potential mechanisms related to for-
mation of pleural effusion after RFA treatment. 
 
REFERENCES 
1. Lozano R, Naghavi M, Foreman K, et al. Global 
and regional mortality from 235 causes of death 
for 20 age groups in 1990 and 2010: a systematic 
analysis for the Global Burden of Disease Study 
2010. Lancet 380: 2095-128, 2012. 
2. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular 
W. C. Chao et al./JCRP 2(2015) 22-30 29
carcinoma: clinical frontiers and perspectives. 
Gut 63: 844-55, 2014. 
3. Bruix J, Sherman M, American Association for 
the Study of Liver D. Management of hepatocel-
lular carcinoma: an update. Hepatology 53: 1020- 
2, 2011. 
4. Lin SM. Local ablation for hepatocellular carci-
noma in Taiwan. Liver Cancer 2: 73-83, 2013. 
5. Woo S, Lee JM, Yoon JH, et al. Small- and me-
dium-sized hepatocellular carcinomas: monopolar 
radiofrequency ablation with a multiple-electrode 
switching system-mid-term results. Radiology 
268: 589-600, 2013. 
6. Meloni MF, Andreano A, Laeseke PF, et al. 
Breast cancer liver metastases: US-guided percu-
taneous radiofrequency ablation--intermediate and 
long-term survival rates. Radiology 253: 861-9, 
2009. 
7. Solbiati L, Livraghi T, Goldberg SN, et al. Percu-
taneous radio-frequency ablation of hepatic me-
tastases from colorectal cancer: long-term results 
in 117 patients. Radiology 221: 159-66, 2001. 
8. Solbiati L, Ahmed M, Cova L, et al. Small liver 
colorectal metastases treated with percutaneous 
radiofrequency ablation: local response rate and 
long-term survival with up to 10-year follow-up. 
Radiology 265: 958-68, 2012. 
9. Van Tilborg AA, Meijerink MR, Sietses C, et al. 
Long-term results of radiofrequency ablation for 
unresectable colorectal liver metastases: a poten-
tially curative intervention. Br J Radiol 84: 556- 
65, 2011. 
10. Curley SA, Marra P, Beaty K, et al. Early and late 
complications after radiofrequency ablation of 
malignant liver tumors in 608 patients. Ann Surg 
239: 450-8, 2004. 
11. Koda M, Murawaki Y, Hirooka Y, et al. Compli-
cations of radiofrequency ablation for hepatocel-
lular carcinoma in a multicenter study: an analysis 
of 16,346 treated nodules in 13 283 patients. 
Hepatol Res 42: 1058-64, 2012. 
12. Moskowitz H, Platt RT, Schachar R, et al. Roent-
gen visualization of minute pleural effusion. An 
experimental study to determine the minimum 
amount of pleural fluid visible on a radiograph. 
Radiology 109: 33-5, 1973. 
13. Livraghi T, Solbiati L, Meloni MF, et al. Treat-
ment of focal liver tumors with percutaneous ra-
dio-frequency ablation: complications encoun-
tered in a multicenter study. Radiology 226: 441- 
51, 2003. 
14. Lai-Fook SJ. Pleural mechanics and fluid ex-
change. Physiol Rev 84: 385-410, 2004. 
15. Stewart PB. The rate of formation and lymphatic 
removal of fluid in pleural effusions. J Clin In-
vest 42: 258-62, 1963. 
16. Koda M, Ueki M, Maeda Y, et al. Percutaneous 
sonographically guided radiofrequency ablation 
with artificial pleural effusion for hepatocellular 
carcinoma located under the diaphragm. AJR Am 
J Roentgenol 183: 583-8, 2004. 
17. Rhim H, Lim HK, Kim YS, et al. Percutaneous 
radiofrequency ablation with artificial ascites for 
hepatocellular carcinoma in the hepatic dome: ini-
tial experience. AJR Am J Roentgenol 190: 91-8, 
2008. 
18. Lee EJ, Rhim H, Lim HK, et al. Effect of artificial 
ascites on thermal injury to the diaphragm and 
stomach in radiofrequency ablation of the liver: 
experimental study with a porcine model. AJR 
Am J Roentgenol 190: 1659-64, 2008. 
19. Kang TW, Rhim H, Lee MW, et al. Radiofre-
quency ablation for hepatocellular carcinoma 
abutting the diaphragm: comparison of effects of 
thermal protection and therapeutic efficacy. AJR 
Am J Roentgenol 196: 907-13, 2011. 
20. Lieberman FL, Hidemura R, Peters RL, et al. 
Pathogenesis and treatment of hydrothorax com-
plicating cirrhosis with ascites. Ann Intern Med 
64: 341-51, 1966.  
30 W. C. Chao et al./JCRP 2(2015) 22-30
